WO2007054085A3 - Antivirales mittel umfassend tribomechanisch aktiviertes zeolith (tmaz), propolis und kolostrum - Google Patents

Antivirales mittel umfassend tribomechanisch aktiviertes zeolith (tmaz), propolis und kolostrum Download PDF

Info

Publication number
WO2007054085A3
WO2007054085A3 PCT/DE2006/002008 DE2006002008W WO2007054085A3 WO 2007054085 A3 WO2007054085 A3 WO 2007054085A3 DE 2006002008 W DE2006002008 W DE 2006002008W WO 2007054085 A3 WO2007054085 A3 WO 2007054085A3
Authority
WO
WIPO (PCT)
Prior art keywords
colostrum
propolis
tmaz
antiviral agent
activated zeolite
Prior art date
Application number
PCT/DE2006/002008
Other languages
English (en)
French (fr)
Other versions
WO2007054085A2 (de
Inventor
Tihomir Lelas
Original Assignee
Ljubicic Mijo
Ivkovic Slavko
Tihomir Lelas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ljubicic Mijo, Ivkovic Slavko, Tihomir Lelas filed Critical Ljubicic Mijo
Priority to BRPI0618529-0A priority Critical patent/BRPI0618529A2/pt
Publication of WO2007054085A2 publication Critical patent/WO2007054085A2/de
Publication of WO2007054085A3 publication Critical patent/WO2007054085A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A61K35/644—Beeswax; Propolis; Royal jelly; Honey
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Insects & Arthropods (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Husbandry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Die Erfindung betrifft antivirale pharmazeutische Mittel, die insbesondere tribomechanisch aktivierte Zeolithe und Propolis und/oder Kolostrum umfassen, sowie die Verwendung dieser Mittel, bevorzugt für HIV-und Hepatitis-Infektionen.
PCT/DE2006/002008 2005-11-11 2006-11-10 Antivirales mittel umfassend tribomechanisch aktiviertes zeolith (tmaz), propolis und kolostrum WO2007054085A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BRPI0618529-0A BRPI0618529A2 (pt) 2005-11-11 2006-11-10 meio antiviral, abrangendo zeólitos ativados em forma tribomecánica, própolis e colostro

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005054306.5 2005-11-11
DE102005054306 2005-11-11

Publications (2)

Publication Number Publication Date
WO2007054085A2 WO2007054085A2 (de) 2007-05-18
WO2007054085A3 true WO2007054085A3 (de) 2008-03-20

Family

ID=37763799

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2006/002008 WO2007054085A2 (de) 2005-11-11 2006-11-10 Antivirales mittel umfassend tribomechanisch aktiviertes zeolith (tmaz), propolis und kolostrum

Country Status (2)

Country Link
BR (1) BRPI0618529A2 (de)
WO (1) WO2007054085A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR069539A1 (es) * 2007-07-25 2010-02-03 Tibotec Pharm Ltd Avances respecto de las formulaciones de comprimidos contra el vih
HRP20080158A2 (hr) * 2008-04-03 2009-10-31 Institut Ru�er Bo�kovi� Sastav i upotreba farmaceutskog pripravka za prevenciju i terapiju bolesti uzrokovanih infekcijama virusom herpes simplex tip 1 i herpes simplex tip 2
IT1401589B1 (it) * 2010-08-03 2013-07-26 Ecobase Gmbh Zeoliti ad azione neuroprotettiva.
EP2609926B1 (de) * 2011-12-30 2013-10-23 Jakob Hraschan Vorbeugung oder Behandlung schmerzhafter Polyneuropathien mittels Verabreichung eines Aluminiumsilikats
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
EP2870967A1 (de) * 2013-11-08 2015-05-13 Glock Health GmbH Behandlung entzündlicher Darmerkrankungen mit Klinoptilolith
EP3167890A1 (de) * 2015-11-12 2017-05-17 Glock Health, Science and Research GmbH Behandlung von vaginitis
CN110074978A (zh) * 2019-03-13 2019-08-02 安庆瑄宇医药科技有限公司 一种缬更昔洛韦组合片剂及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006002816A1 (de) * 2006-01-19 2007-07-26 Klinomed Institut für angewandte Nanotechnologie und Nanomedizin GmbH Mittel zur Therapie und Prophylaxe von HIV

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006002816A1 (de) * 2006-01-19 2007-07-26 Klinomed Institut für angewandte Nanotechnologie und Nanomedizin GmbH Mittel zur Therapie und Prophylaxe von HIV

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
GEKKER ET AL: "Anti-HIV-1 activity of propolis in CD4<+> lymphocyte and microglial cell cultures", JOURNAL OF ETHNOPHARMACOLOGY, ELSEVIER SCIENTIFIC PUBLISHERS LTD, IE, vol. 102, no. 2, 19 July 2005 (2005-07-19), pages 158 - 163, XP005122329, ISSN: 0378-8741 *
GRCE M ET AL: "Antiviral properties of clinoptilolite", MICROPOROUS AND MESOPOROUS MATERIALS, ELSEVIER SCIENCE PUBLISHING, NEW YORK, US, vol. 79, no. 1-3, 1 April 2005 (2005-04-01), pages 165 - 169, XP004784522, ISSN: 1387-1811 *
HARISH Z ET AL: "SUPPRESSION OF HIV-1 REPLICATION BY PROPOLIS AND ITS IMMUNOREGULATORY EFFECT", DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, BIOSCIENCE EDIPRINT INC, vol. 23, no. 2, 1997, pages 89 - 96, XP000857159, ISSN: 0378-6501 *
IVKOVIC SLAVKO ET AL: "DIETARY SUPPLEMENTATION WITH THE TRIBOMECHANICALLY ACTIVATED ZEOLITE CLINOPTILOLITE IN IMMUNODEFICIENCY: EFFECTS ON THE IMMUNE SYSTEM", ADVANCES IN THERAPY, HEALTH COMMUNICATIONS, METUCHEN, NJ, US, vol. 21, no. 2, March 2004 (2004-03-01), pages 135 - 147, XP009077384, ISSN: 0741-238X *
PAVELIC K ET AL: "Immunostimulatory effect of natural clinoptilolite as a possible mechanism of its antimetastatic ability", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, SPRINGER INTERNATIONAL, BERLIN, DE, vol. 128, no. 1, January 2002 (2002-01-01), pages 37 - 44, XP002302085, ISSN: 0171-5216 *
SOLOMONS N W: "Modulation of the immune system and the response against pathogens with bovine colostrum concentrates", EUROPEAN JOURNAL OF CLINICAL NUTRITION, vol. 56, no. suppl 3, 2002, pages s24 - s28, XP009093932 *
STEPHAN W ET AL: "ANTIBODIES FROM COLOSTRUM IN ORAL IMMUNOTHERAPY", JOURNAL OF CLINICAL CHEMISTRY & CLINICAL BIOCHEMISTRY, BERLIN, DE, vol. 28, no. 1, January 1990 (1990-01-01), pages 19 - 23, XP000670034 *

Also Published As

Publication number Publication date
WO2007054085A2 (de) 2007-05-18
BRPI0618529A2 (pt) 2011-09-06

Similar Documents

Publication Publication Date Title
WO2007054085A3 (de) Antivirales mittel umfassend tribomechanisch aktiviertes zeolith (tmaz), propolis und kolostrum
EP2431379A3 (de) HCV-Hemmer
WO2004112687A3 (en) Antiviral acylguanidine compounds and methods
WO2008127364A3 (en) Antiviral compounds and use thereof
EP1865967A4 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung viraler infektionen und anderer erkrankungen
WO2007026024A3 (en) Benzodiazepines as hcv inhibitors
WO2002062290A3 (en) Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
WO2006066079A3 (en) Pyridazinone compounds
WO2008115281A3 (en) Compounds for treating viral infections
TW200716631A (en) Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof
WO2007041487A3 (en) Viral peptides and their use to inhibit viral infections against viruses of the flaviridae family
WO2005063734A3 (de) Substituierte thiophene
SG163517A1 (en) Antiviral compounds and methods
WO2010084115A3 (en) Antiviral agents
WO2004011478A3 (en) Anti-viral 7-deaza d-nucleosides and uses thereof
CL2004000930A1 (es) Compuesto derivado de dihidroquinazolina de formula definida, util para el tratamiento y/o profilaxis de infecciones virales; composicion farmaceutica que comprende al compuesto y uso del compuesto en la preparacion de medicamentos.
WO2008079159A3 (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
WO2006101538A3 (en) Andrographolide derivatives to treat viral infections
WO2006110831A3 (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
WO2021262826A3 (en) 1&#39;-cyano nucleoside analogs and uses thereof
SG10201501376XA (en) Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
WO2008073982A3 (en) 5,6-dihydro-1h-pyridin-2-one compounds
WO2004018461A3 (en) Antibacterial benzoic acid derivatives
WO2006089664A3 (de) Heterocyclylamid-substituierte imidazole
CL2004000710A1 (es) Composicion antimicrobiana y antiparasitaria formada por un antibiotico derivado del cloranfenicol o tianfenicol, un endectocida y por lo menos un vehiculo aceptable, y su uso para tratar enfermedades respiratorias y parasitarias de los bovinos.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase

Ref document number: 06828514

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: PI0618529

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080512